Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Gonyautoxin 3** is a naturally occurring marine toxin belonging to the group of paralytic shellfish poisons known as gonyautoxins, which are sulfated derivatives of saxitoxin. It functions as a highly selective **blocker of voltage-gated sodium channels** (VGSCs), inhibiting sodium ion influx in excitable cells and thereby preventing action potential propagation. This property leads to neuromuscular blockade and paralysis at sufficient concentrations. Gonyautoxin 3 is under investigation as an analgesic for acute pain, such as low back pain and for perioperative pain control after procedures like total knee arthroplasty. It is structurally classified as a small molecule, bis-guanidinium derivative, and is typically detected in the context of marine toxin monitoring. The compound is being developed as part of mixtures (notably with gonyautoxin 2) for clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gonyautoxin 3.